Comparative survival analysis in patients with pulmonary metastases from nasopharyngeal carcinoma treated with radiofrequency ablation

详细信息	查看全文 | 推荐本文 |

• 作者：Chang-chuan Pan^a ; ^b ; Pei-hong Wu^b ; Jing-rui Yu^a ; Wang Li^b ; Zi-lin Huang^b ; Jian-peng Wang^b ; Ming Zhao^b ; ^{zhaoming@sysucc.org.cn}
• 关键词：Radiofrequency ablation ; Nasopharyngeal carcinoma ; Pulmonary metastases ; Metastatic overall survival
• 刊名：European Journal of Radiology
• 出版年：2012
• 期刊代码：93_0720048x
• 类别：med
• 出版时间：April, 2012
• 卷：81
• 期：4
• 页码：e473-e477
• 文件大小：452 K

摘要

Purpose

The aim of this retrospective study was to evaluate technical efficacy and the impact of CT-guided pulmonary radiofrequency ablation (RFA) on survival in patients with pulmonary metastases from nasopharyngeal carcinoma (NPC).

Materials and methods

Between 2000 and 2009, 480 patients were pathologically or clinically confirmed pulmonary metastases from NPC. And ten included patients of them had a total of 23 pulmonary metastases treated with percutaneous RFA under the real-time CT fluoroscopy. Safety, local tumor progression, and survival were evaluated in our institutions. Matched-pair survival was compared using Kaplan-Meier analysis.

Results

A total of 25 ablations were performed to 23 pulmonary metastases in 13 RFA sessions. Pneumothorax requiring chest tube placement developed in 3 of 13 (23.1%) RFA sessions. The median metastatic overall survival was 36.1 months for all the 480 NPC patients with pulmonary metastases. Furthermore, matched-pair analysis demonstrated patients with RFA treatment had a greater metastatic overall survival than patients without RFA treatment (77.1 months vs 32.4 months, log-rank test, p = 0.009). There were no statistically significant differences in the survival probability of patients with RFA treatment (n = 10) and surgical resection of pulmonary metastases (n = 27) (log-rank test, p = 0.75).

Conclusion

CT-guided pulmonary RFA is safe and offers a treatment alternative for local tumor control, providing promising survival in selected patients with pulmonary metastases from NPC.